type of patch, page-11

Rich 52,

This is from the OBJ prospectus for the rights which were issued at the beginning of this month. Make of it what you will:

"The DP and ETP delivery platforms are early-stage technologies that require significant further development to evaluate, optimise and validate the delivery systems for future transdermal product development.

The Company has engaged third party consultants and initiated various study and evaluation programs to identify and optimise the key technology, equipment and skin modelling with the aim of improving the reliability and repeatability of DP and ETP enhanced drug diffusion,

A successful proof-of-concept program must be achieved for the DP and ETP.

The drug delivery market has a lower risk profile than new drug development. However, international regulatory authorities are requiring more extensive clinical trials to show evidence of safety and efficacy for new transdermal products, and further changes to regulatory requirements for drug/device combinations may increase the development costs and time to market. Subject to the successful achievement of in vivo proof-of-concept, OBJ plans to leverage the OBJ Group's platform delivery technologies to develop effective transdermal solutions for existing approved drugs to reduce development costs and timelines."

Cheers